PR83600

VERONA, Italy, 7 April, 2020 /PRNewswire=KYODO JBN/ --

CROMSOURCE, an international contract research organization (CRO) with its

global headquarters in Verona, Italy, has announced that it has initiated its

first COVID-19 trial on behalf of a European pharmaceutical company. This trial

is expected to be performed in Italy, though additional studies are planned by

CROMSOURCE for other countries in Europe as well as the United States.

"The COVID-19 pandemic has created an unprecedented global health and economic

crisis. While all the work we have done in the previous twenty-two years of our

operations has been critical in improving and saving lives, we are particularly

proud to play such an important role in developing a safe and effective

treatment for COVID-19," said Dr. Oriana Zerbini, Founder and CEO of

CROMSOURCE. "The current global situation is humbling to us all, and we look

forward to all global citizens returning to their daily routines."

"In response to the COVID-19 situation CROMSOURCE immediately formed a

multi-disciplinary operational task force to ensure we continue to manage

ongoing projects effectively, according to the most up to date regulatory

guidance and incorporating innovative approaches to trial management as

required," commented Kerry Dyson, Chief Operating Officer. "These steps also

ensured our readiness to rapidly and effectively launch clinical trials for

COVID-19 therapies, demonstrated by our support of this important new study."

About CROMSOURCE

CROMSOURCE is an ISO-certified, international contract research organization

providing a comprehensive portfolio of services to the pharmaceutical,

biotechnology, and medical device industries. Specializing in clinical

development and staffing solutions, we offer a flexible approach to ensure our

clients' unique needs are supported. CROMSOURCE is unparalleled in offering an

End-to-End Guarantee covering trial timelines, enrollment, and price.

CROMSOURCE operates offices across all regions of Europe and North America. For

more information, visit www.cromsource.com.

Logo: https://mma.prnewswire.com/media/663606/CROMSOURCE_Logo.jpg

Contact Info

Margherita Mosconi

margherita.mosconi@cromsource.com

+39-045-8222-811

SOURCE: CROMSOURCE